SEC Form 4 · accession 0001140361-17-047241
BioPharmX Corp · BPMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory David Kitchener
Officer — Chief Financial Officer
Period of report
Dec 20, 2017
Accepted (ET)
Dec 22, 2017 · 6:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001504167
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $0.10 | Dec 20, 2017 | A | 900,000 | A | — | Dec 20, 2027 | Common Stock | 900,000 | 900,000 | D |
| Employee Stock Option (right to buy)F1 | $0.20 | Dec 20, 2017 | A | 414,000 | A | — | Dec 20, 2027 | Common Stock | 414,000 | 414,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable ratably over 36 months